Tag Archives | biotech portfolios and ETFs

FED Rallies Market But Biotech Stocks Are Lagging…Update-1

Update-1 Stealth End of Month Rally Stops Biotech Slide IBB up 3.4% In July and up 1% on Last Day Stocks roared out of the box on Friday but could not hold and ended flat. NASDAQ Up 2.3% for July. Most biotech stocks were green and momentum players came back in to support their favorites: BLUE, JUNO, KITE, […]

Continue Reading 0

Macro to the Forefront with Concerns about Slower China Growth…Update-2

Update-2 …7/29 12:15 EDT… New post at market close Biotech reversal down with other sectors up; post to follow at close. Reiterate caution.NASDAQ up 0.22%, IBB down 1.3%, XBI down 2.39%, Medivation (MDVN) down over 12% to $90.9 with no news but on 7/13 JMP securities cut estimates on lower Xtandi sales. Moreover concerns may […]

Continue Reading 0

2015 Rayno Biopharmaceutical Stock Portfolio

The Biotech Bull Market Is Now in its Sixth Year Led By Biopharmaceuticals Here is the current Rayno Biopharmaceutical Stock Portfolio as of 7/13 prices: Top winners since inception (2009) are: Regeneron (REGN), Alexion (ALXN) and Biogen (BIIB). Winners 2015 YTD are Fibrocell Sciences (FCSC) up 109%, Seattle Genetics (SGEN) up 47.7%, Celldex Therapeutics (CLDX) […]

Continue Reading 0

Biotech Stocks Sell-Off on China, Greece and Network Outages…Update-1 Rally Mode

7/13/15 12N EDT Roller Coaster Market MACRO to sidelines A wave of optimism reverses concerns about China and Greece. China stocks have recovered because there is still growth potential. Although a Greek deal is not finalized the glass is half full again and a Grexit looks off the table. Apparently any Greek deal is a […]

Continue Reading 0

Biotech Bull Market Rolls On in a Volatile Q2 2015: XBI Up 12.4%

Dealmaking and Fast Money Fuel Biotechs Q2 2015 Review Despite a major down trend at the end of April and the recent sell-off, the sector outperformed in Q2 of 2015. The S&P was down 1% and flat YTD. The XBI Biotech ETF continues to be the sector ETF leader up 12.41% compared to 5% for the […]

Continue Reading 0